PE/Cyanine7 anti-human CD8 Antibody
- 产品名称：
- PE/Cyanine7 anti-human CD8 Antibody
- 产品类别：
- 抗体
- 产品编号：
- 344711
- 产品应用：
- 344711
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 1932 |
1 |
- Verified Reactivity
- Human, Cynomolgus, Rhesus
- Reported Reactivity
- African Green, Chimpanzee, Pigtailed Macaque, Sooty Mangabey
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
Clone SK1 recognizes the a chain of CD8. Additional reported applications (for the relevant formats) include: proteogenomics8, immunohistochemistry of acetone-fixed frozen tissue sections, and spatial biology (IBEX)9,10.?This clone was tested in-house and does not demonstrate utility for formalin-fixed paraffin-embedded (FFPE) human tonsil sections.
- Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
- Application References
(PubMed link indicates BioLegend citation) -
- Ledbetter JA, et al. 1981. J. Exp. Med. 153:310.
- Campanelli R, et al. 2002. Intl. Immunol. 14:39.
- Evans RL, et al. 1981. Immunol. 78:544.
- Wooldridge L, et al. 2005. J. Bio. Chem. 280:27491.
- Ch'el IL, et al. 2011. J Exp Med. 208:633. PubMed
- Carbone A, et al. 1999. Blood 93:2319. (IHC-F)
- Ahmed A, et al. 2001. J. Pathol. 193:383. (IHC)
- Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
- Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
- Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
- Product Citations
-
- Hohmann MS, et al. 2021. JCI Insight. 6:. PubMed
- Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
- Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
- Ho CH, et al. 2021. Arthritis Res Ther. 23:199. PubMed
- Manukyan G, et al. 2020. Auto Immun Highlights. 11:5. PubMed
- Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
- Wang H, et al. 2022. iScience. 25:105065. PubMed
- Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
- Buchan SL et al. 2018. Immunity. 49(5):958-970 . PubMed
- Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
- Liu R, et al. 2021. Commun Biol. 4:652. PubMed
- Iannetta M, et al. 2016. PLoS One. 11: 0160277. PubMed
- Arif S, et al. 2020. Diabetologia. 63(6):1186-1198.. PubMed
- Alsaleh G, et al. 2020. Elife. 9: . PubMed
- Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed
- , et al. 2021. Eur J Immunol. 51:2708. PubMed
- James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
- Neal JT, et al. 2018. Cell. 175:1972. PubMed
- Batikan O, et al. 2022. J Coll Physicians Surg Pak. 32:1004. PubMed
- Dai G, et al. 2021. JCI Insight. 6:. PubMed
- Lima J, et al. 2016. Reprod Sci. 10.1177/1933719116653680. PubMed
- Lickliter JD, et al. 2020. Drug Des Devel Ther. 14:1177. PubMed
- Franco LM, et al. 2019. J Exp Med. 216:384. PubMed
- Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
- Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
- Chen Y, et al. 2020. Cell. 1496:183. PubMed
- Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed
- Pierce CA, et al. 2020. Sci Transl Med. 12:00. PubMed
- Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
- Gussarow D, et al. 2021. Front Med (Lausanne). 8:770381. PubMed
- Castellano E, et al. 2022. Front Immunol. 13:970931. PubMed
- Reitinger C, et al. 2022. Front Immunol. 13:970290. PubMed
- van Beek JJP, et al. 2020. Cell Reports. 30(4):1027-1038.e4.. PubMed
- RRID
- AB_2044007 (BioLegend Cat. No. 344711) AB_2687201 (BioLegend Cat. No. 344750) AB_2044008 (BioLegend Cat. No. 344712)
- Structure
- Ig superfamily, homodimer or heterodimer with CD8b, 32-34 kD
- Distribution
-
Majority of thymocytes, T cell subset, NK cells
- Function
- MHC class I co-receptor, thymic differentiation, T cell activation
- Ligand/Receptor
- MHC Class I molecules
- Cell Type
- NK cells, T cells, Thymocytes
- Biology Area
- Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.
- Gene ID
- 925 View all products for this Gene ID
- UniProt
- View information about CD8 on UniProt.org
